Literature DB >> 21332183

High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions.

Brendan Prideaux1, Véronique Dartois, Dieter Staab, Danielle M Weiner, Anne Goh, Laura E Via, Clifton E Barry, Markus Stoeckli.   

Abstract

MALDI-MSI is a powerful technology for localizing drug and metabolite distributions in biological tissues. To enhance our understanding of tuberculosis (TB) drug efficacy and how efficiently certain drugs reach their site of action, MALDI-MSI was applied to image the distribution of the second-line TB drug moxifloxacin at a range of time points after dosing. The ability to perform multiple monitoring of selected ion transitions in the same experiment enabled extremely sensitive imaging of moxifloxacin within tuberculosis-infected rabbit lung biopsies in less than 15 min per tissue section. Homogeneous application of a reference standard during the matrix spraying process enabled the ion-suppressing effects of the inhomogeneous lung tissue to be normalized. The drug was observed to accumulate in granulomatous lesions at levels higher than that in the surrounding lung tissue from 1.5 h postdose until the final time point. MALDI-MSI moxifloxacin distribution data were validated by quantitative LC/MS/MS analysis of lung and granuloma extracts from adjacent biopsies taken from the same animals. Drug distribution within the granulomas was observed to be inhomogeneous, and very low levels were observed in the caseum in comparison to the cellular granuloma regions. In this experiment the MALDI-MRM-MSI method was shown to be a rapid and sensitive method for analyzing the distribution of anti-TB compounds and will be applied to distribution studies of additional drugs in the future.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21332183      PMCID: PMC3158846          DOI: 10.1021/ac1029049

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  18 in total

1.  Antibiotic abscess penetration: fosfomycin levels measured in pus and simulated concentration-time profiles.

Authors:  Robert Sauermann; Rudolf Karch; Herbert Langenberger; Joachim Kettenbach; Bernhard Mayer-Helm; Martina Petsch; Claudia Wagner; Thomas Sautner; Rainer Gattringer; Georgios Karanikas; Christian Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 2.  Principles of antibiotic penetration into abscess fluid.

Authors:  Claudia Wagner; Robert Sauermann; Christian Joukhadar
Journal:  Pharmacology       Date:  2006-07-19       Impact factor: 2.547

3.  MALDI mass spectrometric imaging of biological tissue sections.

Authors:  Tatiana C Rohner; Dieter Staab; Markus Stoeckli
Journal:  Mech Ageing Dev       Date:  2005-01       Impact factor: 5.432

Review 4.  Antibiotic penetration in the respiratory tract and implications for the selection of antimicrobial therapy.

Authors:  D Honeybourne
Journal:  Curr Opin Pulm Med       Date:  1997-03       Impact factor: 3.155

5.  Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

Authors:  J L Johnson; D J Hadad; W H Boom; C L Daley; C A Peloquin; K D Eisenach; D D Jankus; S M Debanne; E D Charlebois; E Maciel; M Palaci; R Dietze
Journal:  Int J Tuberc Lung Dis       Date:  2006-06       Impact factor: 2.373

Review 6.  In-vitro activities of quinolones against mycobacteria.

Authors:  J A Garcia-Rodriguez; A C Gomez Garcia
Journal:  J Antimicrob Chemother       Date:  1993-12       Impact factor: 5.790

7.  Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS.

Authors:  R M Caprioli; T B Farmer; J Gile
Journal:  Anal Chem       Date:  1997-12-01       Impact factor: 6.986

Review 8.  Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.

Authors:  Véronique Dartois; Clifton E Barry
Journal:  Curr Clin Pharmacol       Date:  2010-05

9.  Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

Authors:  William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  2006-05-04       Impact factor: 21.405

10.  Quantitative analysis of small pharmaceutical drugs using a high repetition rate laser matrix-assisted laser/desorption ionization source.

Authors:  Panos Hatsis; Stephan Brombacher; Jay Corr; Peter Kovarik; Dietrich A Volmer
Journal:  Rapid Commun Mass Spectrom       Date:  2003       Impact factor: 2.419

View more
  103 in total

1.  Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.

Authors:  Marcela Henao-Tamayo; Andrés Obregón-Henao; Elizabeth Creissen; Crystal Shanley; Ian Orme; Diane J Ordway
Journal:  Clin Vaccine Immunol       Date:  2014-11-12

2.  Spatial Quantification of Drugs in Pulmonary Tuberculosis Lesions by Laser Capture Microdissection Liquid Chromatography Mass Spectrometry (LCM-LC/MS).

Authors:  Matthew Zimmerman; Landry Blanc; Pei-Yu Chen; Véronique Dartois; Brendan Prideaux
Journal:  J Vis Exp       Date:  2018-04-18       Impact factor: 1.355

Review 3.  Qualitative and quantitative mass spectrometry imaging of drugs and metabolites in tissue at therapeutic levels.

Authors:  Na Sun; Axel Walch
Journal:  Histochem Cell Biol       Date:  2013-07-24       Impact factor: 4.304

4.  High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  Contemp Clin Trials       Date:  2020-01-22       Impact factor: 2.226

5.  An In Vitro Caseum Binding Assay that Predicts Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Hsin-Pin Ho Liang; Danielle Weiner; Jacqueline Gonzales; Laura E Via; Véronique Dartois
Journal:  J Vis Exp       Date:  2017-05-08       Impact factor: 1.355

6.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

7.  High-speed tandem mass spectrometric in situ imaging by nanospray desorption electrospray ionization mass spectrometry.

Authors:  Ingela Lanekoff; Kristin Burnum-Johnson; Mathew Thomas; Joshua Short; James P Carson; Jeeyeon Cha; Sudhansu K Dey; Pengxiang Yang; Maria C Prieto Conaway; Julia Laskin
Journal:  Anal Chem       Date:  2013-10-03       Impact factor: 6.986

8.  The Need for Speed in Matrix-Assisted Laser Desorption/Ionization Imaging Mass Spectrometry.

Authors:  Boone M Prentice; Richard M Caprioli
Journal:  Postdoc J       Date:  2016-03

Review 9.  Matrix-assisted laser desorption ionization imaging mass spectrometry: in situ molecular mapping.

Authors:  Peggi M Angel; Richard M Caprioli
Journal:  Biochemistry       Date:  2013-01-16       Impact factor: 3.162

10.  Prediction of Drug Penetration in Tuberculosis Lesions.

Authors:  Jansy P Sarathy; Fabio Zuccotto; Ho Hsinpin; Lars Sandberg; Laura E Via; Gwendolyn A Marriner; Thierry Masquelin; Paul Wyatt; Peter Ray; Véronique Dartois
Journal:  ACS Infect Dis       Date:  2016-07-06       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.